A specific primer and detection method for a hepatitis B virus splicing variant
By designing PCR primer pairs SEQ ID NO.63 and SEQ ID NO.64, we achieved highly sensitive and specific detection of HBV splicing variants of four genotypes (A, B, C, and D), solving the detection challenges in existing technologies and evaluating the disease progression and treatment efficacy in patients with chronic hepatitis B.
Patent Information
- Application Number
- CN202610983978.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-03
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2046-07-03
AI Technical Summary
Existing technologies are insufficient for efficiently, rapidly, and specifically detecting the four HBV splice variants sp1, sp2, sp4, and sp15 of the A, B, C, and D genotypes distributed in China, and cannot effectively assess their risk of disease progression and treatment efficacy in patients with chronic hepatitis B.
A set of PCR primer pairs, including forward primer SEQ ID NO.63 and reverse primer SEQ ID NO.64, was designed to simultaneously detect four HBV splice variants sp1, sp2, sp4 and sp15 of genotypes A, B, C and D in biological samples using real-time PCR, avoiding specific binding with wild-type HBV or other viruses and improving the specificity and sensitivity of detection.
It achieves high sensitivity and specificity in detecting splicing variants of four HBV genotypes (A, B, C, and D), and can assess the high risk of patients developing liver fibrosis, cirrhosis, liver failure, and liver cancer, as well as predict disease progression and antiviral treatment efficacy in patients with chronic hepatitis B.
Smart Images

Figure CN122521919B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical detection technology, and more specifically to an in vitro detection method for hepatitis B virus. Background Technology
[0002] Persistent infection with hepatitis B virus (HBV) causes chronic hepatitis B. As the disease progresses, persistent chronic hepatitis B can lead to liver fibrosis, cirrhosis, liver failure, and liver cancer, seriously threatening human health. The factors leading to HBV-mediated liver disease are not fully understood, but research suggests that HBV splicing variants may be a contributing factor.
[0003] HBV is a hepatotropic DNA virus whose genome consists of a 3.2 kb partially double-stranded relaxed circular DNA (rcDNA). Based on 8% genomic sequence variation, HBV is distributed globally in nine different genotypes: A, B, C, D, E, F, G, H, and I. In China, genotypes A, B, C, and D are present. HBV particles (i.e., Dane particles) are internalized into cells via the hepatocyte transmembrane transport protein sodium taurocholate cotransporter (NTCP) receptor. Once inside the hepatocyte, the rcDNA is repaired in the nucleus, forming a covalently closed circular DNA (cccDNA) existing as a mini-chromosome. This cccDNA serves as a transcription template, generating 3.5 kb, 2.4 kb, 2.1 kb, and 0.7 kb HBV mRNAs. The 3.5 kb mRNA contains two types: precore mRNA (transcription initiated from the 1783 nt HBV genome) and pgRNA (transcription initiated from the 1818 nt HBV genome), with the former being slightly longer than the latter. Prenuclear mRNA is translated to generate HBeAg, or e antigen, which is an important marker of HBV replication. pgRNA is translated into the core protein and DNA polymerase (pol) protein; simultaneously, it is encased in a nucleocapsid formed by the core protein and used by pol protein as a template for reverse transcription to synthesize rcDNA (90%) or double-stranded linear DNA (dsl DNA, 10%). The nucleocapsid-encapsulated rcDNA uncoats and recycles back into the nucleus to replenish the cccDNA pool, or acquires the HBsAg viral envelope and is secreted extracellularly to infect new hepatocytes.
[0004] Since the first identification of spliced HBV RNA sp1 (single splice variant) and sp10 (double splice variant) processed from pgRNA in the livers of HBV-infected patients in 1989 using Northern blot detection, 20 splice variants from different pgRNA sources have been discovered, named sp1-sp20 respectively. Among them, sp1 is the most common HBV splice variant, which is a 2.2 kb molecule. The splice donor of sp1 is located at 2447 nt with the sequence GT, and the splice acceptor is located at 489 nt with the sequence AG. In addition, three double splice variants, sp2, sp4, and sp15, share the same 2447 nt / 489 nt splice site as the single splice variant sp1.
[0005] In HBV-infected hepatocellular carcinoma cell lines, sp1 accounts for up to 30% of total pgRNA; while in HBV patients, sp1 accounts for 50%–60% of all detected splice variants (according to HBV gene amplification gel electrophoresis analysis of human blood samples). Some HBV alternative splice RNAs are reverse transcribed into DNA by HBV viral polymerase, producing defective HBV viral particles. Therefore, HBV defective DNA reverse transcribed from splice variant RNA can be detected in circulating blood. Studies have shown that the amount of spliced HBV RNA is higher in human liver cancer cells than in non-liver cancer cells. Clinically, defective particles from sp1 RNA can be detected in almost all patients with high HBV replication, and in some patients, sp1 DNA can account for more than 70% of the total circulating viral DNA.
[0006] A study analyzing HBV spRNA types using next-generation sequencing results from 20 patients found that serum spRNAs accounted for as much as 19.02% of the total. sp1, sp2, sp3, sp4, and sp5 were the most common splicing variants. Multivariate analysis showed that patients with elevated spRNA levels had a 2.566-fold higher risk of cirrhosis. In vitro experiments also confirmed that spRNAs contribute to hepatic stellate cell activation, which is crucial in the development of liver fibrosis. Increased HBV spRNA expression poses a risk to liver disease progression.
[0007] The protein encoded by the HBV sp1 splice variant, called hepatitis B spliced protein (HBSP), is a 93-amino acid fusion protein. It originates from the polymerase start codon and contains the N-terminal 47 amino acids of the polymerase, followed by 46 amino acid residues resulting from a new sequence generated downstream of the splice site. HBSP has been reported to promote the migration and invasion of HCC cells and induce apoptosis in liver cancer cells. Furthermore, the core truncated protein HBc-Cys encoded by sp1 promotes nucleocapsid formation, which is essential for HBV infection. Clinical studies have found a positive correlation between the proportion of circulating defective particles generated by sp1 RNA and the severity of liver inflammation and fibrosis; an increased proportion of sp1-derived defective particles before HCC development suggests that sp1 splice variants are associated with the risk of liver fibrosis and hepatocellular carcinoma development, and may serve as a potential biomarker for the clinical management of HBV-related liver disease.
[0008] Therefore, it is urgent to develop a sensitive, rapid, and highly specific detection reagent that can simultaneously detect the presence of four HBV splice variants sp1 (A, B, C, and D) and other common splice variants distributed in China in ex vivo biological samples from patients with chronic hepatitis B. Summary of the Invention
[0009] This invention relates, in one aspect, to a set of PCR primer pairs for simultaneously detecting four HBV splice variants sp1, sp2, sp4, and sp15 of genotypes A, B, C, and D in biological samples. These primer pairs include a forward primer as shown in sequence SEQ ID NO. 63 and a reverse primer as shown in sequence SEQ ID NO. 64. The biological samples may be ex vivo blood, plasma, serum, saliva, or liver tissue from HBV-infected patients, or ex vivo blood, plasma, serum, saliva, or liver tissue from in vitro HBV animal models, or cell supernatant or cells cultured in HBV cell models.
[0010] A second aspect of this invention relates to the use of the aforementioned set of PCR primer pairs in the simultaneous detection of four HBV genotypes (A, B, C, and D) sp1, sp2, sp4, and sp15 in biological samples. The biological samples described herein are isolated blood, plasma, serum, saliva, or liver tissue from HBV-infected patients, or isolated blood, plasma, serum, saliva, or liver tissue from in vitro HBV animal models, or cell supernatant or cells cultured in HBV cell models.
[0011] A third aspect of this invention relates to a method for simultaneously detecting four HBV genotypes (A, B, C, and D) sp1, sp2, sp4, and sp15 in a biological sample, comprising the step of amplifying nucleic acids, including DNA, RNA, or DNA and RNA, from the biological sample using the aforementioned set of PCR primers. The biological sample is isolated blood, plasma, serum, saliva, or liver tissue from an HBV-infected patient; or isolated blood, plasma, serum, saliva, or liver tissue from an in vitro HBV animal model; or cell supernatant or cells cultured in an HBV cell model.
[0012] The fourth aspect of the present invention relates to a kit for simultaneously detecting four genotypes of HBV splicing variants sp1, sp2, sp4 and sp15 (A, B, C and D) in biological samples, comprising the PCR primer pairs described above.
[0013] The fifth aspect of this invention relates to the use of the primer pairs described above in the preparation of a detection reagent for detecting whether a patient is infected with one or more of the four genotypes of hepatitis B (AD), a detection reagent for assessing a patient's high risk of developing liver fibrosis, cirrhosis, liver failure, or liver cancer, a detection reagent for assessing the risk of disease progression in patients with chronic hepatitis B, or a detection reagent for assessing the effectiveness of treatment for hepatitis B in patients.
[0014] The sixth aspect of the present invention relates to a detection kit for detecting whether a patient is infected with one or more of the four genotypes of Alzheimer's disease (AD) HBV, which comprises the PCR primer pairs described above in the present invention.
[0015] The seventh aspect of the present invention relates to a kit for assessing a patient’s high risk of developing liver fibrosis, cirrhosis, liver failure or liver cancer, comprising the PCR primer pairs described above.
[0016] The eighth aspect of the present invention relates to a kit for assessing the risk of disease progression in patients with chronic hepatitis B, comprising the PCR primer pairs described above.
[0017] The ninth aspect of the present invention relates to a kit for evaluating the therapeutic effect of hepatitis B in patients, comprising the PCR primer pairs described above.
[0018] The PCR primers of this invention enable the simultaneous, highly sensitive, and specific detection of four HBV genotypes (A, B, C, and D) in a single test. The detected splicing variants include the common sp1 splicing variant and sp2, sp4, and sp15 splicing variants with the same splicing region. For ease of description, sp1, sp2, sp4, and sp15 are collectively referred to as sp1* in this application. Optionally, sp1* splicing variant DNA or RNA in the blood can be detected, or all nucleic acids of the sp1* splicing variant, including DNA and RNA, can be selectively detected in a single test. Selective analysis can be performed on the ratio of sp1* RNA to total HBV RNA, the ratio of sp1* DNA to total HBV DNA, or the ratio of sp1* total nucleic acid to total HBV nucleic acid. Quantitative detection of sp1* splicing variants is of paramount importance in predicting disease progression and antiviral treatment, and even in the prognosis of patients with chronic hepatitis B. Furthermore, the PCR primer pairs of the present invention can avoid specific binding with wild-type HBV or other viruses and human genes, thereby preventing the amplification of false-positive genes and improving the specificity of detection. Attached Figure Description
[0019] Figure 1 This is a conservation analysis diagram of the sequence near the HBV sp1 splice donor. The vertical line separating CAAT and GTTA marks the splice site of the sp1 splice donor; the sequence after GTTA is spliced out.
[0020] Figure 2 This is a conservation analysis diagram of the sequence near the HBV sp1 splice acceptor. The vertical line separating AG and GA marks the splice site of the sp1 splice acceptor, where the sequence before AG is spliced out.
[0021] Figure 3 This is the Sanger sequencing validation map of the constructed pcDNA3.1-sp1 plasmid. The splitting marker is located between ATGTTC and ATTGAG, and after reverse complementation, it is located between CTCAAT and GAACAT, which is the splice site at 2447 nt and 489 nt.
[0022] Figure 4A , Figure 4B and Figure 4C This is a typical PCR gel electrophoresis specificity analysis diagram of the sp1* transverse primer. M stands for Trans 2K Plus DNA Marker. Figure 4AIn the template, 1: F1 / R1 primer-pcDNA3.1-dsl template, 2: F1 / R1 primer-pcDNA3.1-sp1 template, 3: F1 / R1 primer-water template; 4: F2 / R2 primer-pcDNA3.1-dsl template, 5: F2 / R2 primer-pcDNA3.1-sp1 template, 6: F2 / R2 primer-water template; Figure 4B In the template, 7: F1 / R1-1 primer-pcDNA3.1-dsl template; 8: F1 / R1-1 primer-pcDNA3.1-sp1 template; 9: F1 / R1-1 primer-water template; 10: F3 / R1-1 primer-pcDNA3.1-dsl template; 11: F3 / R1-1 primer-pcDNA3.1-sp1 template; 12: F3 / R1-1 primer-water template; 13: F3 / R3 primer-pcDNA3.1-dsl template; 14: F3 / R3 primer-pcDNA3.1-dsl template. 15: F3 / R3 primer-pcDNA3.1-sp1 template; 16: F1 / R3 primer-pcDNA3.1-dsl template; 17: F1 / R3 primer-pcDNA3.1-sp1 template; 18: F1 / R3 primer-water template; 19: F4 / R4 primer-pcDNA3.1-dsl template; 20: F4 / R4 primer-pcDNA3.1-sp1 template; 21: F4 / R4 primer-water template. Figure 4C In the template, 22: F4 / R4 primer-water template, 23: F4 / R4 primer-pcDNA3.1-dsl template, 24: F4 / R4 primer-pcDNA3.1-sp1 template.
[0023] Figure 5A and Figure 5B This is a graph showing the results of specific analysis by quantitative real-time PCR. Figure 5A The qPCR amplification curves are based on pcDNA3.1-sp1-E+06, pcDNA3.1-dsl-E+06, and water as templates. Figure 5B The results show the melting curves of qPCR using pcDNA3.1-sp1-E+06, pcDNA3.1-dsl-E+06, and water as templates. Only the pcDNA3.1-sp1 E+06 plasmid was amplified normally, and its melting curve showed a single peak; neither the pcDNA3.1-dsl E+06 plasmid nor water was amplified.
[0024] Figure 6A , Figure 6B and Figure 6C This is a diagram illustrating the process of establishing the primer standard curve. Figure 6A The qPCR amplification curves are based on pcDNA3.1-sp1-E+03~E+10 as templates. Figure 6BThe melting curves of qPCR using pcDNA3.1-sp1-E+03~E10 as templates are shown. Figure 6C The standard curve was established using pcDNA3.1-sp1-E+03~E10 as a template.
[0025] Figure 7 It is a linear fitting curve diagram for the linearity investigation of the invented primers.
[0026] Figure 8 This is a qPCR amplification curve for evaluating the precision of the primers, specifically the qPCR amplification curves for 12 replicates of pcDNA3.1-sp1 plasmid at two concentrations: 1.36E+06 copies / mL and 6.8E+03 copies / mL. Detailed Implementation
[0027] Currently, there are at least nine different HBV genotypes (AI) globally, and four AD genotypes exist in China. To enable simultaneous detection of all four AD HBV genotypes in China using quantitative real-time PCR of HBV splice variants, this invention designs PCR primers by analyzing conserved regions of the AD genotype HBV reference sequence in GenBank (specific HBV genotypes, reference sequence numbers, and sequences near the sp1 splice site are shown in Table 1 below) using MegAlign software. Then, a cross-span primer design is performed on the 2447 nt splice donor and 489 nt splice acceptor of sp1 and their nearby sequences. In this application, cross-span primer design is defined as designing primers by selecting multiple combinations of nucleotide sequence fragments in the HBV reference sequence that are not consecutive to the wild-type reference sequence at both ends of the sp1 splice site (2447 nt / 489 nt).
[0028] After the above-mentioned cross-sectional design and experimental screening, it was found that a forward primer spanning 2447 nt 5' and 489 nt 3', namely F4 (SEQ ID NO. 63), could only amplify HBV splice variant templates (sp1, sp2, sp4, and sp15) that share a common splicing site with sp1 during quantitative real-time PCR amplification, while unspliced wild-type HBV templates could not be amplified. Further screening revealed that F4 and R4 (SEQ ID NO. 64) as a primer pair could achieve the objective of this invention, namely, to simultaneously amplify splice variants sp1, sp2, sp4, and sp15 of the four HBV genotypes A, B, C, and D present in China. Using the above-mentioned set of nucleotide primers of this invention, the splice variants sp1, sp2, sp4, and sp15 of HBV genotypes A, B, C, and D can be detected simultaneously with high sensitivity and accuracy in a single detection. The sp1 splicing variant is a common type of splicing variant. The sp2, sp4, and sp15 splicing variants share the same splicing region as sp1. For ease of description, sp1, sp2, sp4, and sp15 are collectively referred to as sp1* in this application. Optionally, sp1* splicing variant DNA or RNA in blood can be detected, or all nucleic acids of the sp1* splicing variant, including DNA and RNA, can be selectively detected at once. Selective analysis can be performed on the ratio of sp1* RNA to total HBV RNA, the ratio of sp1* DNA to total HBV DNA, or the ratio of sp1* total nucleic acid to total HBV nucleic acid. Furthermore, the PCR primer pair combination of this invention can avoid specific binding with wild-type HBV or other viruses and human genes, thereby preventing false-positive gene amplification and improving detection accuracy.
[0029] It is noteworthy that this invention discovered that the sequence near the sp1 splice site of the AD genotype is not very conserved, especially the sequence near the 489 nt site, where 3 out of only 6 bases exhibit diversity, resulting in only 50% identity. However, through the design and screening of this invention, primers with high coverage, specificity, and sensitivity were still obtained, without the need to design multiple probes to simultaneously detect HBV splice variants of the four AD genotypes. This is unexpected for those skilled in the art. Furthermore, those skilled in the art typically consider the 3-5 bp specificity of the 3' end of the primer when designing specific primers. Therefore, when designing primers for amplifying splice variants, they avoid having too many bases at the 3' end pairing with non-splice variant templates (e.g., wild-type templates). However, this invention, through design and experimental screening, found that the primer 3' end pairs with up to 10 bp of non-splice variant templates, yet still exhibits very high specificity for amplifying splice variants, making it an effective specific primer for amplifying splice variants. This is also unexpected for those skilled in the art.
[0030] Because PCR amplification of patient blood using the forward and reverse primers of this invention can simultaneously amplify the sp1* splice variant of all four AD genotypes, i.e., it can simultaneously detect sp1, sp2, sp4, and sp15 without missing the sp1* splice variant of all four AD genotypes, PCR amplification using a pair of primers of this invention can detect one or more genotypes of HBV A, B, C, and D. To achieve the above-mentioned objectives of this invention, PCR amplification using the primers of this invention can be performed using methods well-known in the art, including but not limited to conventional PCR, nested PCR, and quantitative real-time PCR. However, due to the advantages of quantitative real-time PCR, such as its simplicity, speed, and sensitivity, it is preferred. Therefore, a set of primers of this invention can be used to prepare a detection reagent for detecting whether a patient carries one or more sp1* splice variants of the AD genotype, or to prepare a detection reagent for detecting whether a patient is infected with one or more HBV genotypes of the AD. The aforementioned detection reagents include, but are not limited to, kits. Therefore, this invention also relates to a kit for detecting whether a patient is infected with one or more HBV genotypes of the AD. The kit includes the primer pair described above. Other components of the kit, such as the composition, content, and preparation of the buffer solution, are well known to those skilled in the art.
[0031] Since the PCR primer pair of the present invention can simultaneously amplify four HBV splice variants sp1*, biological samples containing the splice variant sp1* can all achieve the purpose of amplification and detection. For example, the splice variant sp1* is present in ex vivo blood, plasma, serum, saliva, liver tissue, etc. from HBV infected patients, ex vivo blood, plasma, serum, saliva, liver tissue, etc. from in vitro HBV animal models, or cell supernatant, cells, etc. from HBV cell models. Therefore, the biological samples described in the present invention include, but are not limited to, the above-mentioned ex vivo blood, plasma, serum, saliva, liver tissue, cell supernatant, cells, etc.
[0032] Because the PCR primer pair of the present invention can simultaneously detect splicing variants sp1*, namely sp1, sp2, sp4, and sp15, and studies have found that a high proportion of splicing variants sp1* predicts a high risk of liver fibrosis, cirrhosis, liver failure, and liver cancer. For example, a longitudinal study of patients with HBV monoinfection before and after liver cancer showed that a high proportion of serum spHBV and wild-type HBV (7% serum spHBV threshold) was significantly associated with liver cancer development. Therefore, the PCR primer pair of the present invention is useful for preparing a diagnostic reagent for assessing a high risk of liver fibrosis, cirrhosis, liver failure, and liver cancer in patients. The diagnostic reagent is, for example, but not limited to, a kit. Therefore, the present invention also relates to a kit for detecting whether a patient has a high risk of liver fibrosis, cirrhosis, liver failure, or liver cancer. The kit includes the PCR primer pair of the present invention, and other components in the kit, such as buffer components, are well known to those skilled in the art. The operating steps of the kit of the present invention for detecting whether a patient has a high risk of liver fibrosis, cirrhosis, liver failure, or liver cancer include: 1. Obtain ex vivo biological samples from the patient to be tested; 2. Extract HBV nucleic acid from biological samples; 3. Using the set of PCR primers described in this invention, the content of HBV splice variant sp1* in biological samples was detected by PCR; 4. Use standard commercial kits to detect the wild-type HBV content in biological samples; 5. Set a threshold for the ratio of splice variant sp1* to wild-type HBV; 6. When the expression level of the splice variant sp1* in the sample of the patient to be tested is higher than the threshold, the patient is determined to be a high-risk group for liver fibrosis, cirrhosis, liver failure or liver cancer.
[0033] For the use of the above kits, the ex vivo biological samples can be blood, plasma, serum, saliva, liver tissue, etc., and the PCR can be conventional PCR, nested PCR, quantitative real-time PCR, etc. The threshold setting is a conventional technique in this field.
[0034] Quantitative detection of sp1* splicing variants is of paramount importance in predicting disease progression and antiviral treatment, and even in the prognosis, of patients with chronic hepatitis B. Therefore, this invention relates to a set of PCR primer pairs for preparing a diagnostic reagent to assess the risk of disease progression in patients with chronic hepatitis B. This diagnostic reagent may include, but is not limited to, kits. Therefore, this invention also relates to a kit for detecting whether a patient with chronic hepatitis B has a risk of disease progression. In such a kit, the set of PCR primer pairs of this invention is included, and other components of the kit, such as buffer components, are well known to those skilled in the art.
[0035] Furthermore, since the presence of splicing variants may be associated with HBV immune escape, the PCR primer pair of the present invention can be used to assess the treatment efficacy of hepatitis B in patients. Therefore, the PCR primer pair of the present invention is useful for preparing a detection reagent for assessing the treatment efficacy of hepatitis B in patients. The detection reagent is, for example, but not limited to, a kit. Therefore, the present invention also relates to a kit for detecting the treatment efficacy of hepatitis B in patients. In the kit, the PCR primer pair of the present invention is included, and other components of the kit, such as buffer composition, content, and preparation, are well known to those skilled in the art. The operating steps of the kit for detecting the treatment efficacy of hepatitis B in patients according to the present invention include: 1. Obtain biological samples from the patient before and after treatment; 2. HBV nucleic acid was extracted from biological samples before and after treatment, respectively; 3. Using the set of PCR primers described in this invention, the content of splice variant sp1* in biological samples before and after treatment was detected by PCR. 4. When the level of sp1* splice variant after treatment is lower than that before treatment or even undetectable, the patient's hepatitis B treatment is considered effective.
[0036] In the above methods, biological samples can be blood, plasma, serum, saliva, liver tissue, etc., and PCR can be conventional PCR, nested PCR, quantitative real-time PCR, etc.
[0037] Optionally, the assay can detect sp1* splice variant DNA or RNA in the blood, or selectively detect all nucleic acids of the sp1* splice variant, including DNA and RNA, in a single assay, and selectively analyze the ratio of sp1* RNA to total HBV RNA. Quantitative detection of sp1* splice variants is of paramount importance in predicting disease progression and antiviral treatment, and even in the prognosis of patients with chronic hepatitis B. Furthermore, the PCR primer pair combination of this invention avoids specific binding with wild-type HBV or other viruses and human genes, thereby preventing false-positive gene amplification and improving detection specificity.
[0038] To explain in detail the technical content, objectives, and effects of the technical solution, the following description is provided in conjunction with specific embodiments.
[0039] Example 1: Conservation analysis of AD type HBV genome sequence
[0040] This invention first downloads the reference sequence of AD genotype HBV from the NCBI database. The specific HBV genotype reference sequence GeneBank sequence number and the sequence adjacent to the sp1 splice site are shown in Table 1. Non-conserved bases are marked with underscores, and slashes " / " indicate splice positions.
[0041] Table 1. HBV genotype reference sequence GeneBank sequence number and adjacent sequences of sp1 splice site
[0042] This invention uses the Clustal W multiple sequence alignment analysis function of MegAlign software to analyze the conserved region near the sp1 splice site. The analysis results are as follows: Figure 1 and 2 As shown.
[0043] Figure 1 This is a conservation analysis diagram of the sequence near the HBV sp1 splice donor. The vertical line separating CAAT and GTTA marks the splice site of the sp1 splice donor. The sequence after GTTA is spliced out. Figure 1 The sequence at the 5' end of the sp1 splice donor is relatively conserved. The 24 bases GATCTCAATCTCGGGAATCTCAAT (SEQ ID NO. 55) immediately adjacent to the 5' end of the sp1 splice donor are completely identical in 27 reference sequences, indicating good conservation. There are 7 base sites of diversity approximately 33-51 bp away from the 5' end of the splice donor site, indicating poor conservation. There are 4 base sites of diversity approximately 52-90 bp away from the 5' end of the splice donor site, indicating relatively conserved sequence.
[0044] Figure 2 This is a conservation analysis diagram of the sequence near the HBV sp1 splice acceptor. The vertical line separating AG and GA marks the splice site of the sp1 splice acceptor, where the sequence before AG is spliced away. Figure 2 The sequence at the 3' end of the sp1 splice acceptor is relatively poorly conserved. In particular, among the 6 bases immediately adjacent to the 3' end of the sp1 splice acceptor, 3 bases exhibit diversity, and 13 base sites within 42 bases show diversity, indicating poor conservation. However, within 43-83 bp from the 3' end of the sp1 splice acceptor, there are 4 base sites showing diversity, indicating acceptable conservation.
[0045] Example 2: Primer Design
[0046] Based on the conservation and specificity analysis of the sequences flanking the sp1 splice site in Example 1, transverse primers were designed for the splice donor at 2447 nt and the splice acceptor at 489 nt, as well as the sequences nearby. These designed primers are referred to as sp1* transverse primers in this application. A total of nine sp1* transverse primers were designed, and their sequence names, locations, sequences, and covered genotypes are shown in Table 2. The nine primers can test seven primer combinations: F1 / R1, F2 / R2, F1 / R1-1, F3 / R1-1, F3 / R3, F1 / R3, and F4 / R4. The primer position refers to the nucleotide position (nt) of the primer sequence in the HBV reference sequence; "W" in the forward and reverse primer sequences is a degenerate base, representing A / T, and "D" in the reverse primer is a degenerate base, representing G / A / T; the covered genotypes are splicing variants of HBV that can be detected using the forward and reverse primers at least four genotypes (AD).
[0047] Table 2. Nine sp1* transverse primer sequences designed successively
[0048] Example 3: Construction of HBV sp1 plasmid
[0049] The pcDNA3.1-sp1 plasmid was artificially constructed, containing the pcDNA 3.1 vector backbone and the HBV C-type sequence with a deletion of 2447nt-489nt. Using the pcDNA3.1-dsl plasmid as a template, the pcDNA3.1-sp1 plasmid was constructed, containing the pcDNA3.1 vector backbone and the full-length C-type HBV dsl-DNA sequence. The specific construction process is as follows.
[0050] Based on the HBV pcDNA3.1-dsl plasmid gene map, forward and reverse primers with a 15-20 bp homologous arm at the 5' end were designed at the sp1 splice site. Forward primer: CAATCTCGGGAATCTCAATGAACATCAACTACCAGCAC (SEQ ID NO. 65), reverse primer: ATTGAGATTCCCGAGATTG (SEQ ID NO. 66).
[0051] Using the pcDNA3.1-dsl plasmid as a template, PCR was performed using high-fidelity DNA polymerase 2×Phanta Flash Master Mix (Nanjing Novizan Biotechnology Co., Ltd., P510) to obtain the target fragment with homologous arms (containing the pcDNA3.1 vector backbone). The PCR reaction volume was 50 μL: 2 μL each of forward and reverse primers (10 μM), 25 μL of 2×Phanta Flash Master Mix, 1 ng of pcDNA3.1-dsl plasmid template, and the remainder was added to a final volume of double-distilled water to 50 μL. The PCR reaction conditions were set as follows: 95℃ pre-denaturation for 5 min; 95℃ denaturation for 10 s, 56℃ annealing for 5 s, 72℃ extension for 40 s, for 30 cycles. The amplification product was detected by 1% agarose gel electrophoresis to confirm its identity as the target fragment, and the target fragment was purified using a gel extraction kit (Beijing Polymer Biotechnology Co., Ltd., MF029).
[0052] Homologous recombination ligation of the purified target fragment was performed using 2×MultiF Seamless Assembly Mix (ABclonal, RK21020): 10 μL of the purified fragment and 10 μL of 2×MultiF Seamless Assembly Mix were mixed and reacted at 50 °C for 15 min.
[0053] Homologous recombination was performed using conventional techniques. The product of homologous recombination was then transformed and cultured in DH5α competent cells (Beijing TransGen Biotech Co., Ltd., CD201). After incubation in LB medium at 37°C for 1 h, the cells were plated onto LB solid medium containing ampicillin and cultured at 37°C for 12-16 h. Plump white single colonies were picked and shaken for incubation. Plasmids were extracted using a plasmid mini-extraction kit (Tiangen Biotech (Beijing) Co., Ltd., TIANGEN, DP118).
[0054] The plasmid construction methods and procedures described above are all common homologous recombination plasmid construction methods and procedures well-known in this industry, and the reagents used are all commercially available.
[0055] The final target fragment sequence near the sp1 splice site is: TCGGGAATCTCAATGAACATCAACTACCAGCACGGGACCATGCAAGACCTGCACGATTCCTGCTCAAGGAACCTCTATGTTTCCCTCTTGTTGCTGT (SEQ ID NO. 67).
[0056] The successfully constructed plasmid and the designed R4 primers were sent to a first-generation sequencing company for Sanger sequencing. Reverse sequencing was used to verify the sequence accuracy. The sequencing verification results are as follows: Figure 3As shown, the arrow indicates the location between ATGTTC and ATTGAG, which, after reverse complementation, corresponds to the junction between CTCAAT and GAACAT, i.e., the splice site between 2447 nt and 489 nt. Sequencing results show that the pcDNA3.1-sp1 plasmid constructed using pcDNA3.1-dsl as a template has, as expected, removed the sequence between 2447 nt and 489 nt, indicating successful construction of the pcDNA3.1-sp1 plasmid.
[0057] Example 4: Conventional PCR Experiment
[0058] Using the pcDNA3.1-sp1 plasmid successfully constructed in Example 3 as a positive control, the pcDNA3.1-dsl plasmid as a negative control, and water as a blank control, PCR amplification was performed. The concentrations of the pcDNA3.1-sp1 and pcDNA3.1-dsl plasmids were determined using Thermo Scientific's Nanodrop (Thermo, Nanodrop 2000), with results of 362.45 ng / μL and 238 ng / μL, respectively. The pcDNA3.1-sp1 plasmid is 6692 bp in length, and the pcDNA3.1-dsl plasmid is 7948 bp in length, with calculated copy number concentrations of 5.29 × 10⁻⁶, respectively. 13 copies / mL, 2.92×10 13 copies / mL, diluted 1×10 6 The template was doubled. Primers were used in seven combinations of nine primers designed in Example 2 (F1 / R1, F2 / R2, F1 / R1-1, F3 / R1-1, F3 / R3, F1 / R3, F4 / R4). PCR was performed using commercially available 2×Taq polymerase (Genstar, A012) from Beijing Kangrun Chengye Biotechnology Co., Ltd. The amplification system was 20 μL, containing 8.2 μL water, 10 μL 2×Taq, 0.4 μL forward primer (10 μM), 0.4 μL reverse primer (10 μM), and 1 μL template. The PCR amplification program was as follows: 94℃ pre-denaturation for 2 min, 1 cycle; 94℃ denaturation for 30 s, 58℃ annealing for 30 s, 72℃ extension for 6 s, 30 cycles; 72℃ final extension for 5 min, 1 cycle.
[0059] The amplification products were detected by 2% agarose gel electrophoresis, and the results are as follows: Figure 4A and Figure 4B As shown. Where M is the Trans 2K Plus DNA Marker from Beijing TransGen Biotech Co., Ltd. Figure 4AIn the template, 1: F1 / R1 primer-pcDNA3.1-dsl template, 2: F1 / R1 primer-pcDNA3.1-sp1 template, 3: F1 / R1 primer-water template; 4: F2 / R2 primer-pcDNA3.1-dsl template, 5: F2 / R2 primer-pcDNA3.1-sp1 template, 6: F2 / R2 primer-water template; Figure 4B In the template, 7: F1 / R1-1 primer-pcDNA3.1-dsl template; 8: F1 / R1-1 primer-pcDNA3.1-sp1 template; 9: F1 / R1-1 primer-water template; 10: F3 / R1-1 primer-pcDNA3.1-dsl template; 11: F3 / R1-1 primer-pcDNA3.1-sp1 template; 12: F3 / R1-1 primer-water template; 13: F3 / R3 primer-pcDNA3.1-dsl template; 14: F3 / R3 primer-pcDNA3.1-dsl template. 15: F3 / R3 primer-pcDNA3.1-sp1 template; 16: F1 / R3 primer-pcDNA3.1-dsl template; 17: F1 / R3 primer-pcDNA3.1-sp1 template; 18: F1 / R3 primer-water template; 19: F4 / R4 primer-pcDNA3.1-dsl template; 20: F4 / R4 primer-pcDNA3.1-sp1 template; 21: F4 / R4 primer-water template. Figure 4A and Figure 4B This indicates that only the F4 / R4 primer combination shown in lanes 19-21 amplified the target band as expected, i.e., the pcDNA3.1-sp1 plasmid template amplified a 97 bp band. Negative control pcDNA3.1-dsl plasmids showed no target band amplification. The F1 / R1 primer combination shown in lanes 1-3 amplified an unexpected band greater than 1000 bp with the negative control pcDNA3.1-dsl template. The F2 / R2 primer combination shown in lanes 4-6 not only amplified an unexpected band greater than 1000 bp with the negative control pcDNA3.1-dsl template, but also exhibited primer dimers less than 100 bp. The F1 / R1-1 primer combination shown in lanes 7-9 failed to amplify the target band. The F3 / R1-1 primers shown in lanes 10-12 amplified a 75 bp target band with the negative control pcDNA3.1-dsl template, which was unexpected and could only be amplified with the theoretically pcDNA3.1-sp1 template, indicating that this primer combination is non-specific. The F3 / R3 primers shown in lanes 13-15 amplified a 108 bp target band with both the negative control pcDNA3.1-dsl template and the blank control water template, which was also unexpected and could only be amplified with the theoretically pcDNA3.1-sp1 template, indicating that this primer combination is highly non-specific.
[0060] The experiment was repeated with the F4 / R4 primer set, and the number of amplification cycles was increased to 35. The results are shown below. Figure 4C In the sequence, M represents the Trans 2K Plus DNA Marker from Beijing TransGen Biotech Co., Ltd., 22: F4 / R4 primer-water template, 23: F4 / R4 primer-pcDNA3.1-dsl template, and 24: F4 / R4 primer-pcDNA3.1-sp1 template. Figure 4C As shown, repeated experiments yielded the same expected results. The pcDNA3.1-dsl plasmid contains the full-length HBV gene sequence and can be used as a wild-type HBV control. Electrophoresis results showed that the invented primers have the specificity to amplify only the splice variant sp1* and are not affected by wild-type HBV.
[0061] Example 5: ddPCR determination of pcDNA3.1-sp1 plasmid
[0062] The successfully validated pcDNA3.1-sp1 plasmid from Example 1 was diluted 1×10⁻⁶. 7 Using the F4 / R4 primers selected in Example 4 as templates, absolute quantification of digital PCR was performed using the TD-1 digital PCR platform instrument of Beijing Xinyi Biotechnology Co., Ltd. (hereinafter referred to as Xinyi) and EvaGreen dPCR SuperMix reagent (Xinyi, 23102).
[0063] The microdroplet formation system (30 μL) consisted of: 15 μL of 2×EvaGreen dPCR SuperMix, 0.6 μL each of 10 μM forward and reverse primers, 5 μL of diluted pcDNA3.1-sp1 plasmid template, and 8.8 μL of double-distilled water to a total volume of 30 μL.
[0064] Microdroplet generation: Remove the microdroplet generation chip from the universal sample preparation kit (Xinyi, 10001), add 30 μL of mixed reagent and template to the corresponding "water" well (avoiding air bubbles), add 160 μL of microdroplet generation oil to the "oil" well, cover the water and oil wells with the microdroplet generation chip sealing gasket, and place it in the Xinyi sample preparation instrument (Xinyi, Digital PCR TD-1) to generate droplets.
[0065] PCR was performed within half an hour after microdroplet generation. The PCR reaction program was set as follows: 95℃ pre-denaturation for 10 min; 94℃ denaturation for 30 s, 60℃ annealing extension for 1 min, 45 cycles; instrument cooling at 12℃ for 5 min; the temperature change rate was set to 1.5℃ / s.
[0066] After PCR, place the microdroplet detection chip from the eight-cell microdroplet detection kit (Xinyi, 10002) containing the PCR product into the corresponding positions of the detection chip mechanical clamp of the biochip analyzer (Xinyi, Digital PCR TD-1). Add 450 μL and 500 μL of microdroplet detection oil to the first row of wells (small wells) and the second row of wells (large wells) of the chip, respectively. After sealing the chip with a gasket, place it on the biochip analyzer for microdroplet analysis.
[0067] The measured concentration was multiplied by the dilution factor to obtain the original concentration of pcDNA3.1-sp1 plasmid as 1.36E+13 copies / mL.
[0068] Example 6: Real-time PCR Experiment
[0069] The pcDNA3.1-sp1 plasmid and the pcDNA3.1-dsl plasmid were diluted 1×10⁻⁶ each. 7 Quantitative real-time PCR (qPCR) amplification was performed at concentrations up to E+06 copies / mL, with water as a blank control. Each sample was replicated twice. PCR was performed using commercially available SYBR Green qPCR enzyme (Genstar, ZA301-101S) from Beijing Kangrun Chengye Biotechnology Co., Ltd. The qPCR amplification system was 20 μL, containing 7.2 μL water, 10 μL 2×Taq mix, 0.4 μL forward primer (10 μM), 0.4 μL reverse primer (10 μM), and 2 μL template. The qPCR amplification program was: 95℃ pre-denaturation for 2 min, 1 cycle; 95℃ denaturation for 15 s; 60℃ annealing and extension for 30 s, 45 cycles. A melting curve program was added according to the quantitative real-time PCR instrument. A Roche LightCycler 480 quantitative real-time PCR instrument was used for qPCR amplification, signal collection, melting reaction, and result analysis.
[0070] The qPCR amplification results are shown in Figure 5. Figure 5A The qPCR amplification curves are based on pcDNA3.1-sp1-E+06, pcDNA3.1-dsl-E+06, and water as templates. Figure 5B The results show the melting curves of qPCR using pcDNA3.1-sp1-E+06, pcDNA3.1-dsl-E+06, and water as templates. The experimental results indicate that only the pcDNA3.1-sp1 E+06 plasmid was amplified normally, exhibiting a classic S-shaped amplification curve, and the melting curve showed a single peak. Neither the pcDNA3.1-dsl E+06 plasmid nor water was amplified, indicating that the invented primers have high specificity, are not affected by wild-type templates, and produce a single amplification product using sp1 as a template.
[0071] Example 7: Establishment of Standard Curve and Linearity Examination
[0072] The pcDNA3.1-sp1 plasmid, digitally PCR-defined in Example 5, was serially diluted to obtain plasmids of 1.36E+10 copies / mL, 1.36E+09 copies / mL, 1.36E+08 copies / mL, 1.36E+07 copies / mL, 1.36E+06 copies / mL, 1.36E+05 copies / mL, 6.8E+03 copies / mL, 1.36E+03 copies / mL, and 6.8E+02 copies / mL for qPCR amplification. The qPCR amplification system was 50 μL, including 25 μL of 2×Taq mix, 1 μL of forward primer (10 μM), 1 μL of reverse primer (10 μM), and 23 μL of template. The qPCR amplification program was: 95℃ pre-denaturation for 5 min, 1 cycle; 95℃ denaturation for 15 s; 60℃ annealing and extension for 30 s, 45 cycles. Following the amplification program, a melting curve program was added based on the quantitative PCR instrument. This experiment used a Roche LightCycler 480 quantitative PCR instrument for qPCR amplification, signal collection, melting reaction, and result analysis.
[0073] The qPCR amplification results are shown in Figure 6. Figure 6A The qPCR amplification curves are based on pcDNA3.1-sp1-E3~E10 templates. Figure 6B The melting curves of qPCR using pcDNA3.1-sp1-E3~E10 as templates are shown. Figure 6C The standard curve was established using pcDNA3.1-sp1-E3~E10 as templates. Experimental results showed that the melting curves of qPCR amplification using pcDNA3.1-sp1E+03~E+10 as templates were uniform, all within the range of 80℃-85℃. Figure 6B The qPCR amplification curves for eight different concentration gradients exhibited a standard S-shape. Figure 6A The obtained Ct values are shown in Table 3 below.
[0074] Table 3. Template concentration and Ct value for qPCR amplification
[0075] The standard curves plotted for the 8 concentrations are as follows: Figure 6C As shown, the slope is -3.43, corresponding to an amplification efficiency of 95.7%, which falls between 90% and 110%. The correlation coefficient R0 is [missing value]. 2 =0.9993>0.98, indicating a good linear relationship.
[0076] The determination of linear range is as follows: First, assess the accuracy of the test results by calculating the absolute deviation (B) of the logarithmic value for each concentration sample: B = MT (where M is the detected value of Log copies / mL, and T is the theoretical value of the Log copies / mL concentration). If the absolute deviation (B) of the logarithmic value for each concentration does not exceed ±0.5 Log, then the accuracy of this concentration sample meets the requirements and can be used for linear range analysis. Then, using the logarithmic value of the theoretical concentration as X and the logarithmic value of the actual detected concentration as Y, perform linear fitting and calculate the linear correlation coefficient R. 2 If R 2 If R is ≥0.980, then the concentration series is within the linear range. 2 Cases close to 1 show good correlation. The detection results are shown in Table 4 below.
[0077] Table 4. Absolute deviation of logarithmic values for each concentration sample
[0078] Fitting the data in the table above, the resulting linear fitting curve is as follows: Figure 7 As shown. According to Figure 7 It can be seen that the correlation coefficient R in the fitted curve 2 =0.9984, close to 1, indicating a good linear correlation.
[0079] Example 8: Sensitivity Detection Experiment
[0080] The pcDNA3.1-sp1 plasmid, digitally determined by PCR in Example 5, was serially diluted to five lower concentrations, specifically, the plasmid diluted to 1.36E+03 copies / mL was further diluted 2×, 5×, 10×, and 20×, yielding plasmids of 680 copies / mL, 272 copies / mL, 136 copies / mL, and 68 copies / mL, respectively. qPCR was performed according to the amplification system and procedure described in Example 7, and the detection results are shown in Table 5 below.
[0081] Table 5. Detection rate of low-concentration plasmid qPCR
[0082] Probit regression analysis showed that the limit of detection was 175.08 copies / mL, corresponding to 4.02 copies / reaction.
[0083] Example 9: Precision
[0084] Two concentrations of pcDNA3.1-sp1 plasmid, 1.36E+06 copies / mL and 6.8E+03 copies / mL, were used for 12 replicates each. The qPCR detection system and procedure were as described in Example 7 above. The qPCR amplification curves of the replicate tests are shown below. Figure 8 As shown, the Ct values obtained from the detection were used to calculate the detection concentration based on the standard curve constructed as described in Example 7. The coefficient of variation (CV,%) was calculated using the logarithm of the quantitative detection results for samples of the same concentration (CV = standard deviation / average value × 100%). The CV% calculation results of the logarithm of the detection concentration are shown in Table 6 below. The CV% obtained for the two samples with medium and low concentrations were both less than 5%.
[0085] Table 6. Calculation results of CV% of the logarithm of the detection concentration
[0086] Example 10: sp1* DNA detection from ex vivo plasma samples from clinical settings
[0087] Preparation of ex vivo HBV DNA samples: Nucleic acid extraction and purification of clinical ex vivo plasma samples were prepared using the QIAamp DNA Mini Kit (QIAGEN, 51304).
[0088] Quantitative real-time PCR experiment: The HBV sp1* DNA in the isolated blood of 18 patients with chronic hepatitis B who had not received antiviral treatment or whose condition rebounded after stopping medication was detected using the quantitative real-time PCR method of the present invention according to Example 7.
[0089] Blood HBV DNA levels were detected using a commercially available HBV DNA quantitative detection kit (Roche Diagnostics cobas 4800 system, Hepatitis B Virus Nucleic Acid Quantitative Detection Kit (PCR-Fluorescence Method), National Medical Device Registration Certificate 20183400500).
[0090] The results showed that HBV sp1* DNA was widely present in the ex vivo blood of patients with chronic hepatitis B who had not received antiviral treatment or whose condition rebounded after discontinuation of treatment. The levels ranged from E+04 copies / mL to E+07 copies / mL, as shown in Table 7 below.
[0091] Table 7. HBV DNA and HBV sp1* DNA levels in ex vivo blood samples from 18 patients with chronic hepatitis B.
[0092] Example 11: Detection of sp1* DNA in isolated clinical liver biopsy samples
[0093] Total DNA was extracted from ex vivo liver biopsy tissue of a patient with acute-on-chronic liver failure (ACLF) using the QIAamp DNA Mini Kit (QIAGEN, 51304). The non-circular linear DNA was then digested with PSAD enzyme (Plasmid-Safe ATP-DependentDNase, LGC, E3101K), leaving covalently closed circular DNA, i.e., cccDNA. The DNA products from the PSAD-digested ex vivo liver biopsy tissue of this ACLF patient were detected for HBV sp1* DNA using the quantitative real-time PCR method of this invention, as described in Example 7.
[0094] The results showed that the HBV sp1* DNA or sp1* cccDNA content in the isolated liver tissue of this patient with acute-on-chronic liver failure was as high as 1.79E+05 copies / mL. This suggests that the patient with liver failure has a closed HBV sp1* DNA replication cycle, which may play a potential role in the progression of liver failure.
Claims
1. A set of PCR primer pairs for simultaneously detecting four HBV splice variants sp1, sp2, sp4, and sp15 of genotypes A, B, C, and D in biological samples, characterized in that, The PCR primer pair includes a forward primer as shown in sequence SEQ ID NO. 63 and a reverse primer as shown in sequence SEQ ID NO.
64.
2. The PCR primer pair according to claim 1, characterized in that, The biological samples mentioned are isolated blood, plasma, serum, saliva, and liver tissue from patients infected with HBV, or isolated blood, plasma, serum, saliva, and liver tissue from in vitro HBV animal models, or cell supernatant and cells cultured in HBV cell models.
3. Use of the PCR primer pair according to claim 1 or 2 in the preparation of a kit for simultaneously detecting four HBV splice variants sp1, sp2, sp4 and sp15 of genotypes A, B, C and D in biological samples.
4. The use as described in claim 3, characterized in that, The biological samples mentioned are ex vivo blood, plasma, serum, saliva, and liver tissue from patients infected with HBV, or ex vivo blood, plasma, serum, saliva, and liver tissue from in vitro HBV animal models, or cell supernatant and cells cultured in HBV cell models.
